vs
查尔斯河实验室（CRL）与RXO, Inc.（RXO）财务数据对比。点击上方公司名可切换其他公司
RXO, Inc.的季度营收约是查尔斯河实验室的1.5倍（$1.5B vs $994.2M），RXO, Inc.净利率更高（-3.1% vs -27.8%，领先24.7%），查尔斯河实验室同比增速更快（-0.8% vs -11.9%），查尔斯河实验室自由现金流更多（$58.6M vs $-9.0M），过去两年RXO, Inc.的营收复合增速更高（26.8% vs -0.9%）
查尔斯河实验室国际是总部位于美国马萨诸塞州威尔明顿的医药及生物技术领域合同研究组织（CRO），成立于1947年，可为新药、疫苗及医疗器械的研发提供临床前和临床阶段的专业实验室服务。
RXO是总部位于美国的头部运输及物流解决方案供应商，核心业务覆盖货运经纪、大件商品最后一公里配送、运输管理服务与全链路供应链优化支持，主要服务北美制造业、零售业及电商领域的客户。
CRL vs RXO — 直观对比
营收规模更大
RXO
是对方的1.5倍
$994.2M
营收增速更快
CRL
高出11.0%
-11.9%
净利率更高
RXO
高出24.7%
-27.8%
自由现金流更多
CRL
多$67.6M
$-9.0M
两年增速更快
RXO
近两年复合增速
-0.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $994.2M | $1.5B |
| 净利润 | $-276.6M | $-46.0M |
| 毛利率 | — | — |
| 营业利润率 | -28.5% | -2.9% |
| 净利率 | -27.8% | -3.1% |
| 营收同比 | -0.8% | -11.9% |
| 净利润同比 | -28.9% | -84.0% |
| 每股收益（稀释后） | $-5.57 | $-0.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CRLRXO
| Q4 25 | $994.2M | $1.5B | ||
| Q3 25 | $1.0B | $1.4B | ||
| Q2 25 | $1.0B | $1.4B | ||
| Q1 25 | $984.2M | $1.4B | ||
| Q4 24 | $1.0B | $1.7B | ||
| Q3 24 | $1.0B | $1.0B | ||
| Q2 24 | $1.0B | $930.0M | ||
| Q1 24 | $1.0B | $913.0M |
净利润CRLRXO
| Q4 25 | $-276.6M | $-46.0M | ||
| Q3 25 | $54.4M | $-14.0M | ||
| Q2 25 | $52.3M | $-9.0M | ||
| Q1 25 | $25.5M | $-31.0M | ||
| Q4 24 | $-214.5M | $-25.0M | ||
| Q3 24 | $69.7M | $-243.0M | ||
| Q2 24 | $94.1M | $-7.0M | ||
| Q1 24 | $73.0M | $-15.0M |
毛利率CRLRXO
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 34.6% | — | ||
| Q2 24 | 34.5% | — | ||
| Q1 24 | 34.1% | — |
营业利润率CRLRXO
| Q4 25 | -28.5% | -2.9% | ||
| Q3 25 | 13.3% | -0.5% | ||
| Q2 25 | 9.7% | — | ||
| Q1 25 | 7.6% | -2.1% | ||
| Q4 24 | -16.7% | -1.4% | ||
| Q3 24 | 11.6% | -1.9% | ||
| Q2 24 | 14.8% | — | ||
| Q1 24 | 12.5% | -1.3% |
净利率CRLRXO
| Q4 25 | -27.8% | -3.1% | ||
| Q3 25 | 5.4% | -1.0% | ||
| Q2 25 | 5.1% | -0.6% | ||
| Q1 25 | 2.6% | -2.2% | ||
| Q4 24 | -21.4% | -1.5% | ||
| Q3 24 | 6.9% | -23.4% | ||
| Q2 24 | 9.2% | -0.8% | ||
| Q1 24 | 7.2% | -1.6% |
每股收益（稀释后）CRLRXO
| Q4 25 | $-5.57 | $-0.28 | ||
| Q3 25 | $1.10 | $-0.08 | ||
| Q2 25 | $1.06 | $-0.05 | ||
| Q1 25 | $0.50 | $-0.18 | ||
| Q4 24 | $-4.17 | $-0.17 | ||
| Q3 24 | $1.33 | $-1.81 | ||
| Q2 24 | $1.74 | $-0.06 | ||
| Q1 24 | $1.30 | $-0.13 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $213.8M | $17.0M |
| 总债务越低越好 | $2.1B | $387.0M |
| 股东权益账面价值 | $3.2B | $1.5B |
| 总资产 | $7.1B | $3.3B |
| 负债/权益比越低杠杆越低 | 0.68× | 0.25× |
8季度趋势，按日历期对齐
现金及短期投资CRLRXO
| Q4 25 | $213.8M | $17.0M | ||
| Q3 25 | $207.1M | $25.0M | ||
| Q2 25 | $182.8M | $18.0M | ||
| Q1 25 | $229.4M | $16.0M | ||
| Q4 24 | $194.6M | $35.0M | ||
| Q3 24 | $210.2M | $55.0M | ||
| Q2 24 | $179.2M | $7.0M | ||
| Q1 24 | $327.0M | $7.0M |
总债务CRLRXO
| Q4 25 | $2.1B | $387.0M | ||
| Q3 25 | $2.2B | $387.0M | ||
| Q2 25 | $2.3B | $387.0M | ||
| Q1 25 | $2.5B | $387.0M | ||
| Q4 24 | $2.2B | $351.0M | ||
| Q3 24 | $2.3B | $352.0M | ||
| Q2 24 | $2.4B | $370.0M | ||
| Q1 24 | $2.7B | $351.0M |
股东权益CRLRXO
| Q4 25 | $3.2B | $1.5B | ||
| Q3 25 | $3.4B | $1.6B | ||
| Q2 25 | $3.4B | $1.6B | ||
| Q1 25 | $3.2B | $1.6B | ||
| Q4 24 | $3.5B | $1.6B | ||
| Q3 24 | $3.8B | $1.7B | ||
| Q2 24 | $3.7B | $579.0M | ||
| Q1 24 | $3.6B | $582.0M |
总资产CRLRXO
| Q4 25 | $7.1B | $3.3B | ||
| Q3 25 | $7.5B | $3.2B | ||
| Q2 25 | $7.6B | $3.2B | ||
| Q1 25 | $7.6B | $3.3B | ||
| Q4 24 | $7.5B | $3.4B | ||
| Q3 24 | $8.0B | $3.4B | ||
| Q2 24 | $7.9B | $1.8B | ||
| Q1 24 | $8.2B | $1.8B |
负债/权益比CRLRXO
| Q4 25 | 0.68× | 0.25× | ||
| Q3 25 | 0.64× | 0.24× | ||
| Q2 25 | 0.70× | 0.24× | ||
| Q1 25 | 0.79× | 0.24× | ||
| Q4 24 | 0.65× | 0.22× | ||
| Q3 24 | 0.62× | 0.21× | ||
| Q2 24 | 0.65× | 0.64× | ||
| Q1 24 | 0.73× | 0.60× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $147.5M | $7.0M |
| 自由现金流经营现金流 - 资本支出 | $58.6M | $-9.0M |
| 自由现金流率自由现金流/营收 | 5.9% | -0.6% |
| 资本支出强度资本支出/营收 | 8.9% | 1.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $518.5M | $-8.0M |
8季度趋势，按日历期对齐
经营现金流CRLRXO
| Q4 25 | $147.5M | $7.0M | ||
| Q3 25 | $213.8M | $23.0M | ||
| Q2 25 | $204.6M | $23.0M | ||
| Q1 25 | $171.7M | $-2.0M | ||
| Q4 24 | $159.4M | $-7.0M | ||
| Q3 24 | $251.8M | $-7.0M | ||
| Q2 24 | $193.5M | $-5.0M | ||
| Q1 24 | $129.9M | $7.0M |
自由现金流CRLRXO
| Q4 25 | $58.6M | $-9.0M | ||
| Q3 25 | $178.2M | $9.0M | ||
| Q2 25 | $169.3M | $9.0M | ||
| Q1 25 | $112.4M | $-17.0M | ||
| Q4 24 | $83.7M | $-19.0M | ||
| Q3 24 | $213.1M | $-18.0M | ||
| Q2 24 | $154.0M | $-16.0M | ||
| Q1 24 | $50.7M | $-4.0M |
自由现金流率CRLRXO
| Q4 25 | 5.9% | -0.6% | ||
| Q3 25 | 17.7% | 0.6% | ||
| Q2 25 | 16.4% | 0.6% | ||
| Q1 25 | 11.4% | -1.2% | ||
| Q4 24 | 8.4% | -1.1% | ||
| Q3 24 | 21.1% | -1.7% | ||
| Q2 24 | 15.0% | -1.7% | ||
| Q1 24 | 5.0% | -0.4% |
资本支出强度CRLRXO
| Q4 25 | 8.9% | 1.1% | ||
| Q3 25 | 3.5% | 1.0% | ||
| Q2 25 | 3.4% | 1.0% | ||
| Q1 25 | 6.0% | 1.0% | ||
| Q4 24 | 7.5% | 0.7% | ||
| Q3 24 | 3.8% | 1.1% | ||
| Q2 24 | 3.8% | 1.2% | ||
| Q1 24 | 7.8% | 1.2% |
现金转化率CRLRXO
| Q4 25 | — | — | ||
| Q3 25 | 3.93× | — | ||
| Q2 25 | 3.91× | — | ||
| Q1 25 | 6.74× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.61× | — | ||
| Q2 24 | 2.06× | — | ||
| Q1 24 | 1.78× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CRL
| Discovery And Safety Assessment Segment | $591.6M | 60% |
| Manufacturing Support Segment | $196.4M | 20% |
| Transferred At Point In Time | $108.0M | 11% |
| Transferred Over Time | $98.3M | 10% |
RXO
| Retail Sector | $546.0M | 37% |
| Last Mile | $298.0M | 20% |
| Food And Beverage Sector | $225.0M | 15% |
| Other Sector | $185.0M | 13% |
| Managed Transportation | $133.0M | 9% |
| Automotive Sector | $93.0M | 6% |
